Published by Global Banking & Finance Review®
Posted on July 8, 2025
1 min readLast updated: January 23, 2026
Novo Nordisk seeks EU approval for a higher dose of Wegovy, with trials showing significant weight loss. This move aims to expand obesity treatment options across Europe.
STOCKHOLM (Reuters) -Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European Medicines Agency for approval, with one in three trial participants achieving 25% or more weight loss.
Novo Nordisk said in a statement it aimed to make the higher dose available throughout the European Union.
"This marks another significant milestone in the company’s goal to provide a broad portfolio of innovative and person-centric solutions to support people living with obesity," it said.
(Reporting by Anna Ringstrom. Editing by Essi Lehto and Mark Potter)
Novo Nordisk submitted a new, higher dose of its obesity treatment Wegovy for approval.
The company aims to make the higher dose available throughout the European Union.
This marks another significant milestone in the company’s goal to provide a broad portfolio of innovative solutions for people living with obesity.
Explore more articles in the Headlines category
